INSIGHTS | CLINICAL OPERATIONS
The disconnect between clinical trial strategy and site reality
Operational issues before a study starts to fall behind.
SHARE THIS ARTICLE
IN THIS ARTICLE
- Gap between strategy and reality
- The 4 pressures on site performance
- When feasibility is just an assumption
- Protocol complexity has operational implications
- The missing perspective at the planning table
- Operational reality includes the patient experience
- From operational alignment to shared accountability
- The value of different perspectives in clinical research
- Sources
Gap between strategy and reality
Clinical development strategy is often defined in terms of milestones. Site activation. First patient enrolled. All patients enrolled. Database lock. Regulatory submission.
There are many assumptions that go into each of these milestones. Resources. Timelines. Patient availability. Operational readiness.
But sometimes those assumptions don’t match the reality of investigative sites.
The protocol may be scientifically sound. But it may be hard to implement in the existing clinical workflow. The enrollment target may be supported by epidemiological data. But what about other studies? What about eligibility criteria? What about the time it takes to find the right patients?
The timeline for the study may seem reasonable. But then you start negotiating contracts,
implementing technology, and training staff. And suddenly, resources are limited.
These aren’t necessarily operational failures. But maybe they indicate that we didn’t have all the information we needed when we made those initial decisions.
Sometimes, the most significant operational disconnects happen before we even start to fall behind on the first milestone.
The 4 pressures on site performance
Clinical trial complexity
Study start-up challenges
Site staffing
Recruitment and retention
These percentages represent the proportion of sites surveyed that listed these issues among their top 3 challenges. They aren’t measures of trial failure.
But what’s interesting is how they’re interconnected.
Protocol complexity can impact staffing requirements. Staffing availability can impact study start-up and patient recruitment. Delays in activation can impact the time we have to get to the enrollment targets. And then, if enrollment is challenging, that can lead to a need for protocol amendments or different operational strategies.
What may seem like a challenge for one function can suddenly become a challenge for the whole study.
When feasibility is just an assumption
The purpose of site feasibility is to determine if a research center has the patients, infrastructure, expertise, and capacity to successfully conduct the study.
But feasibility is only as good as the information we gather and the assumptions we use to make sense of it.
For example, a site may have a large patient population. It seems like it’s in a good position to meet the enrollment expectations on paper.
But just because you have patients doesn’t mean you have the right patients who are interested and available.
The protocol may have frequent visits. Specialized procedures. Strict eligibility criteria. Patients may have issues with transportation. Or competing demands. Or maybe research coordinators are already busy with multiple studies. And there are overlapping demands.
The gap between the theoretical patient availability and the practical enrollment capacity can be significant.
The Clinical Trials Transformation Initiative has emphasized the need to incorporate recruitment considerations into protocol design, trial feasibility, site selection, and communications—not treat recruitment as something we do downstream.
This is important because feasibility isn’t just about determining if a site can participate.
It’s about determining whether the study, as designed, can realistically succeed.
Protocol complexity has operational implications
The protocol defines the scientific and clinical requirements for the trial. But it also defines a lot of the work that investigative sites need to do.
The more assessments, procedures, technology platforms, and documentation required, the more time and resources it may take to conduct the study.
Therapeutic Innovation & Regulatory Science published research in 2024 looking at how we can quantify site participation burden to better understand protocol performance. They note that the existing measures don’t fully capture the burden for investigative site personnel.
This is a limitation.
We may evaluate the protocol for scientific rigor. Or regulatory alignment. Or patient safety. But maybe we don’t fully capture the cumulative demands on the site team.
And it’s not just about the administrative burden. It can impact staffing capacity. Patient experience. Recruitment. Retention. Consistency of study execution.
It’s not about making the protocol less rigorous.
It’s about whether we’re considering operational feasibility as much as we consider scientific goals.
The missing perspective at the planning table
Sponsors have responsibility for clinical trial oversight. CROs may manage a significant amount of trial execution. Investigative sites are responsible for conducting the research with participants under the approved protocol.
They have different perspectives on the study.
Sponsors are considering development strategy, regulatory goals, budgets, and portfolio priorities. CROs are managing operational execution across vendors, regions, and sites. Investigative sites are dealing with the practicalities of scheduling visits, managing patients, procedures, and documentation.
The perspectives are complementary. But not interchangeable.
A sponsor may see a protocol amendment as a necessary strategic adjustment. A CRO may see the impact on timelines and execution. A site may see the need for additional training, updated documentation, patient communication, changes in workflow to implement.
And they’re all right.
The challenge is when one perspective dominates at the planning table, and the other perspectives are only consulted when issues arise.
Collaboration is more than just communicating decisions. It’s about incorporating operational knowledge before decisions are made.
Operational reality includes the patient experience
And there’s one perspective that’s particularly important: the patient experience.
A trial may be operationally feasible for a sponsor or CRO. But it may place a lot of demands on the people we’re asking to participate.
Frequent appointments. Transportation requirements. Complex procedures. Strict eligibility criteria. These can impact whether people are able or willing to enroll and stay in the study.
The FDA’s December 2025 guidance on enhancing participation in clinical trials addresses approaches to eligibility criteria, enrollment practices, and trial design that can help support participation by populations more representative of the people likely to use an approved treatment.
The broader lesson isn’t just about recruitment.
It’s about considering the realities of patients and investigative sites in study planning. And that can help us make better-informed operational decisions.
Patient access. Site capacity. Study feasibility. They’re not separate considerations. They’re interconnected aspects of successful clinical development.
From operational alignment to shared accountability
It’s not about removing uncertainty to close the gap between clinical trial strategy and site reality. There’s always going to be uncertainty in clinical development. Changing conditions. Competing priorities. Trade-offs.
It’s about more discipline in examining assumptions before we make operational commitments.
Experienced clinical research professionals understand the importance of asking questions beyond the next milestone.
What is the evidence for the enrollment assumptions? Have we considered site capacity with the full workload of the protocol? What may be unnecessary burden in the study requirements? How can operational changes impact patients and the site team? Where could early input from another function change the strategy?
These aren’t just questions for sponsors. Or CROs. Or investigative sites.
It’s about shared judgment.
It’s not about shifting the responsibility from one stakeholder to another. It’s about a more complete understanding of the work before we start execution.
The value of different perspectives in clinical research
The Clinical Research Steering Committee (CRSC) brings together experienced clinical research professionals to discuss complex industry challenges from the perspectives of people who have worked in different functions, organizations, and stages of clinical development.
The value of these discussions is the ability to see connections that may not be obvious from a single operational perspective.
Maybe a site challenge is coming from protocol development. Or an enrollment issue is from feasibility assumptions. Or a timeline delay is revealing a decision made earlier about resources or execution.
It’s not just about performance metrics. It’s about experience, informed discussions, and the willingness to challenge assumptions.
Clinical trials are only going to become more demanding. The question is whether the industry can collaborate early enough to prevent predictable challenges from becoming avoidable setbacks.
The best clinical trial strategies aren’t just designed to meet milestones. They’re designed with a realistic understanding of what it takes to get to those milestones.
Sources
- WCG. 2025 Clinical Research Site Challenges Report. October 2025. https://www.wcgclinical.com/insights/2025-clinical-research-site-challenges-report/
- Florez M, Smith Z, Olah Z, Martin M, Getz K. Quantifying Site Burden to Optimize Protocol Performance. Therapeutic Innovation & Regulatory Science. 2024;58:347-356. https://doi.org/10.1007/s43441-023-00602-5
- Clinical Trials Transformation Initiative. Clinical Trials Recruitment Planning: A Proposed Framework. Contemporary Clinical Trials. https://www.sciencedirect.com/science/article/pii/S155171441730753X
- U.S. Food and Drug Administration. Enhancing Participation in Clinical Trials-Eligibility Criteria, Enrollment Practices, and Trial Designs. Final Guidance, December 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-participation-clinical-trials-eligibility-criteria-enrollment-practices-and-trial-designs